Practice Implications of the Atrial Fibrillation Guidelines  by Curtis, Anne B.
Practice Implications of the Atrial Fibrillation Guidelines
Anne B. Curtis, MD*
Atrial ﬁbrillation is one of the most common and complex cardiac arrhythmias. UsingUniversity at B
York. Manuscript
and accepted Janu
The author wa
and revisions of th
development of th
See page 1668
*Correspondin
E-mail addres
0002-9149/13 
http://dx.doi.org/1currently available evidence, leading medical societies have established recommendations for
the optimalmanagement of atrial ﬁbrillation. These guidelines have recently been updated by
4 consensus groups: the European Society of Cardiology, the American College of Chest
Physicians, the Canadian Cardiovascular Society, and a task force of 3 societies from the
United States: the American College of Cardiology Foundation, the American Heart Asso-
ciation, and the Heart Rhythm Society. The present review focused on the similarities and
differences among these recently updated guidelines. Key revisions included updated infor-
mation on newer treatments for rhythm control, treatment options to reduce atrial ﬁbrillation
complications, and updated anticoagulant management for thromboprophylaxis. 2013 Elsevier Inc. Open access under CC BY (Am J Cardiol 2013;111:1660e1670)-NC-ND license.An estimated 3 million Americans and 4.5 million Euro-
peans are affected by atrial ﬁbrillation (AF).1,2 By 2050,
a projected 6 to 16 million Americans will be affected by this
arrhythmia, with similar increases expected in Europe.2,3
Leading medical societies periodically evaluate medical
evidence to provide guidance on the best practices for clini-
cians. The guidelines for the management of AF have recently
been updated by 4 separate consensus groups: the European
Society of Cardiology (ESC), the American College of Chest
Physicians (ACCP), the Canadian Cardiovascular Society
(CCS), and a task force of 3 societies from the United States:
the American College of Cardiology Foundation, American
Heart Association, and Heart Rhythm Society (ACCF/AHA/
HRS).4e15 These new guidelines include updated information
on newer treatments for rhythm control and treatments to
reduce AF complications. Given that much of the morbidity
and mortality in AF is due to stroke and thromboembolism,
thromboprophylaxis is critical to reduce the embolic risk.16
Despite these recommendations,many patientswithAFdo not
receive appropriate thromboprophylaxis.17e19 This underuse
of thromboprophylaxis might be in part because of the dosing
complexities of the anticoagulant warfarin. New options for
anticoagulation for patients with AF have recently become
available and have been described in the new guidelines.
The present review focused on the similarities and
differences among this quartet of updated guidelines, high-
lighting the ACCF/AHA/HRS recommendations and
comparing them with the ESC, ACCP, and CCS guidelines.
Methodology Updates
The classiﬁcation of recommendations and ranking of
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Open access under CC BY-NC-ND license.guidelines are listed in Tables 1 and 2. The updated ACCF/
AHA/HRS methodology separates class III recommenda-
tions into 2 subclasses to delineate whether the recom-
mendation is determined to be of “no beneﬁt” or associated
with “harm” to the patient.14 The CCS also updated its
methodology, introducing the Grading of Recommendations
Assessment Development and Evaluation system for the
classiﬁcation of recommendations and ranking the evidence
level.12 The ACCP also uses the Grading of Recommen-
dations Assessment Development and Evaluation system,
differing only in that the quality of a body of evidence can
be high (A), moderate (B), or low (C).20 For the ninth
edition ACCP guidelines (2012), in addition to experts in
the ﬁeld of thrombosis, clinician experts in methodology
and the interpretation of evidence were added to the panel
and provided the primary leadership responsibilities,
allowing a more rigorous application of the ACCP Grading
of Recommendations Assessment Development and Evalu-
ation approach than previously.20,21
Criteria for Rate Control
The parameters for optimal rate control in patients with
AF are controversial and have no standard method of
assessment. The new ACCF/AHA/HRS guidelines include
a change in the recommended target heart rate—stating that
treatment to achieve strict control of the heart rate is not
beneﬁcial compared with lenient control. The European and
Canadian recommendations have made similar changes,
with subtle differences (Table 3).
This change in the recommended target heart rate was
largely determined from the results of the Rate Control
Efﬁcacy in Permanent Atrial Fibrillation (RACE II) study.
The RACE II study found that strict heart rate control in
patients with AF was not beneﬁcial compared with lenient
control (strict rate control: a heart rate at rest of <80
beats/min and <110 beats/min during moderate exercise;
lenient rate control: a heart rate at rest of <110 beats/min).
A larger proportion of patients treated with the lenient
strategy achieved their target heart rate goal, with lower
drug doses and fewer drug combinations, resulting in far
fewer outpatient visits to achieve the intended target.14,22 In
general, lenient rate control is more convenient (requireswww.ajconline.org
Table 1
Classiﬁcation/grading of recommendations assessment development and evaluation of recommendations*
ACCF/AHA/HRS ESC AACP CCS
Class I Class I Grade 1 (strong) Strong
Conditions for which there is evidence
and/or general agreement that a given
procedure/therapy is beneﬁcial, useful,
and effective
Evidence and/or general agreement that a
given treatment or procedure is beneﬁcial,
useful, and effective
Beneﬁts clearly outweigh
risk and burdens or vice
versa
Class II Class II Grade 2 (weak) Conditional (i.e., weak)
Conditions for which there is conﬂicting
evidence and/or a divergence of opinion
about the usefulness/efﬁcacy of performing
the procedure/therapy
Conﬂicting evidence and/or a divergence
of opinion about the usefulness/efﬁcacy
of the given treatment or procedure
Beneﬁts closely balanced
with risks and burden
Class IIa Class IIa
Weight of evidence/opinion is in favor
of usefulness/efﬁcacy
Weight of evidence/opinion is in favor
of usefulness/efﬁcacy
Class IIb Class IIb
Usefulness/efﬁcacy is less well established
by evidence/opinion
Usefulness/efﬁcacy is less well established
by evidence/opinion
Class III Class III
Conditions for which there is evidence and/or
general agreement that a procedure/therapy
is not useful or effective and in some cases
could be harmful
Evidence or general agreement that the
given treatment or procedure is not
useful/effective, and in some cases
could be harmful
COR III—no beneﬁt
Not useful/effective, no proven beneﬁt
COR III—harm
Could be harmful to patient or excess cost
without beneﬁt
COR ¼ class of recommendation; GRADE ¼ Grading of Recommendations Assessment, Development, and Evaluation.
* Size of treatment effect from top of Table 1 to bottom.
Table 2
Level/quality of evidence and the strength of recommendation
Level of evidence ACCF/AHA/HRS ESC AACP CCS*
A (high) Data derived from multiple
randomized clinical trials
or meta-analyses
Data derived from multiple
randomized clinical trials
or meta-analyses
Consistent evidence from randomized
controlled trials without important
limitations or exceptionally strong
evidence from observational studies
High; future research unlikely
to change conﬁdence in
estimate of effect (e.g.,
multiple well-designed,
well-conducted clinical trials)
B (moderate) Data derived from a single
randomized trial or
nonrandomized studies
Data derived from a single
randomized clinical trial or
large nonrandomized studies
Evidence from randomized controlled
trials with important limitations
(inconsistent results, methodologic
ﬂaws, indirect or imprecise) or very
strong evidence from observational
studies
Moderate; additional research
likely to have an important
effect on conﬁdence in
estimate of effect and might
change the estimate (e.g.,
limited clinical trials,
inconsistency of results or
study limitations)
C (low) Only consensus opinion of
experts, case studies, or
standard-of-care
Consensus of opinion of
experts and/or small studies,
retrospective studies,
registries
Evidence for at least 1 critical outcome
from observational studies, case series,
or randomized controlled trials, with
serious ﬂaws or indirect evidence
Low; additional research very
likely to have a signiﬁcant
effect on estimate of effect
and likely to change estimate
(e.g., small number of clinical
studies or cohort observations)
— — — — Very low; estimate of effect
very uncertain (e.g., case
studies, consensus opinion)
* The CCS uses the GRADE system for ranking the level of evidence (high, moderate, low, very low). The CCS also uses other factors in determining the
strength of the recommendation: (1) difference between desirable and undesirable effects (the greater the difference between the desirable and undesirable
effects, the greater the probability that a strong recommendation is indicated); (2) values and preferences (the greater the variation or uncertainty in values and
preferences, the greater the probability that a conditional recommendation is indicated); (3) cost (the greater the cost, the lower the likelihood that a strong
recommendation is indicated).
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Table 3
New American College of Cardiology Foundation (ACCF)/American Heart Association (AHA)/Heart Rhythm Society (HRS) recommendations compared with European Society of Cardiology (ECS), American
College of Chest Physicians (ACCP), and Canadian Cardiovascular Society (CCS) recommendations
New
Recommendation
ACCF/AHA/HRS ESC ACCP CCS
Heart rate control Strict rate control (<80 beats/min at rest, <110
beats/min during moderate exercise) not beneﬁcial
compared with lenient rate control (<110
beats/min at rest)* (class III—no beneﬁt; level of
evidence B)
Initially, lenient rate control, heart rate at rest of
<110 beats/min (class IIa; level of evidence B); if
symptoms persist or tachycardiomyopathy occurs,
use stricter rate control (class IIa; level of
evidence B)
NR Rate control should aim for heart rate at rest of
<100 beats/min (strong; high-quality
evidence)
Combining
anticoagulant
therapy with
antiplatelet
therapy
Clopidogrel plus aspirin if OAC is unsuitable (class
IIb; level of evidence B); triple therapy generally
not recommended
Clopidogrel plus aspirin only if patients refuse OAC
and bleeding risk is low (class IIa; level of
evidence B); triple therapy: (1) after stenting if
thromboembolic risk is moderate to high; (2) in
short term after ACS or PCI† (class IIa; level of
evidence C)
Triple therapy after stent
placement if CHADS2
2 (grade 2C)
Triple therapy after ACS or PCI if risk of stroke
is high (conditional; low-quality evidence)
Dronedarone Is reasonable in patients with paroxysmal AF or after
conversion of persistent AF (class IIa; level of
evidence B); not for patients with class IV heart
failure or patients with recent decompensated
heart failure (class III—harm; level of evidence B)
Is reasonable to achieve rate control in patients with
recurrent AF (class I; level of evidence A); not for
patients with NYHA class III to IV or unstable
heart failure (class III; level of evidence B); not
for patients in permanent AF (class III)
NR Can be used along with other agents to optimize
rate control (conditional; moderate-quality
evidence); not for patients in permanent AF,
with a history of heart failure, or LVEF 0.40,
and not for the sole purpose of rate control
(strong; high-quality evidence)
Dabigatran An alternative to warfarin in patients without
prosthetic heart valves or hemodynamically
signiﬁcant disease, renal failure, or advanced liver
disease (impaired baseline clotting function); 150
mg twice daily in patients with creatinine
clearance >30 ml/min; 75 mg twice daily in
patients with creatinine clearance 15e30 ml/min
(class I; level of evidence B)
Dabigatran, rivaroxaban,z or apixabanz in preference
to warfarin (class IIa; level of evidence A)
Dabigatran 150 mg twice daily for most patients;
110 mg twice daily for patients 80 yrs old,
concomitant use of interacting drugs (e.g.,
verapamil), HAS-BLED score 3, or in patients
with creatinine clearance 30e49 ml/min (class IIa;
level of evidence B)
150 mg twice daily rather
than VKA, except for
patients with AF and
mitral stenosis, stent,
or CHADS2 1 who
experience ACS
(grade 2B)
Dabigatran, rivaroxaban,x or apixabanx in
preference to warfarin
Dabigatran 150 mg twice daily preferable to
110 mg twice daily, except in certain patients{
(conditional; high-quality evidence)
Catheter-based
ablation
therapy for
maintenance of
sinus rhythm
For signiﬁcantly symptomatic, paroxysmal AF
refractory to antiarrhythmic drugs in some
patientsk (class I; level of evidence A); for
symptomatic persistent AF (class IIa; level of
evidence A); for symptomatic, paroxysmal AF in
patients with signiﬁcant left atrial dilation or with
signiﬁcant LV dysfunction (class IIb; level of
evidence A)
For symptomatic, paroxysmal AF refractory to
antiarrhythmic drugs (class I; level of evidence
A); ﬁrst-line treatment of certain patients with AF
(class IIa, level of evidence B); antiarrhythmic
drugs not a prerequisite in AF patients who remain
symptomatic despite rate-control drugs and no
signiﬁcant underlying heart disease (class IIb;
level of evidence B); for patients with heart failure
and AF refractory to antiarrhythmic drugs (class
IIb; level of evidence B)
NR# For AF refractory to antiarrhythmic drugs in
patients in whom rhythm control remains
desired (strong; moderate-quality evidence);
ﬁrst-line therapy in highly selected patients
with symptomatic, paroxysmal AF
(conditional; low-quality evidence)
ACS ¼ acute coronary syndrome; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, and drugs/alcohol;
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; NR ¼ no recommendation provided in published guidelines; NYHA ¼ New York Heart Association; OAC ¼ oral anticoagulant therapy;
PCI ¼ percutaneous coronary intervention; triple therapy ¼ combination of vitamin K antagonist, aspirin, and clopidogrel; VKA ¼ vitamin K antagonist therapy.
* In patients with permanent AF with LVEF >0.4 and no or acceptable symptoms related to arrhythmia.
† At 3e6 months after ACS with or without PCI; 4 weeks after elective PCI.
z Rivaroxaban was approved for use in Europe in December 2011; the 2012 ECS update has recommended rivaroxaban and included apixaban once approved in Europe (approved in November 2012).
x Approval for rivaroxaban was obtained in Canada January 2012; the 2012 CCS focused update included rivaroxaban and recommended apixaban once approved byHealth Canada (approved in December 2012).44,45
{ Patients of low body weight, decreased renal function, or at increased risk of major bleeding.
k Patients with normal or mildly dilated left atria, normal or mildly reduced LV function, and no severe pulmonary disease.
# The ACCP does not provide speciﬁc recommendations for catheter-based ablation in the management of AF.
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Review/Atrial Fibrillation Clinical Guidelines 1663fewer outpatient visits and examinations) and easier to
achieve. Thus, lenient rate control might be a reasonable
strategy for patients with permanent AF.
The ACCF/AHA/HRS, ESC, and CCS guidelines have all
stated that strict rate control is no longer considered superior
to lenient rate control (Table 3).9,13,14 However, the CCS has
recommended a heart rate target of<100 beats/min at rest for
most patients. This conservative target heart rate might have
been in response to the relatively small number of patients in
the RACE II trial randomized to the lenient rate control group
with a heart rate at rest of >100 to 110 beats/min. Thus, the
safety of a heart rate at rest of>100 beats/min might not have
been conclusively demonstrated. Additionally, at the end of
the ﬁrst year of the RACE II trial, the difference in the heart
rate between the lenient and strict rate-control groups was
actually quite small (mean  SD heart rate at rest of 86  15
and 75  12 beats/min in the lenient and strict rate-control
arms, respectively).23
The updated ACCP guidelines do not provide criteria for
a target heart rate or speciﬁc recommendations for rate-
control strategies. Previous ACCP guidelines (“Pharmaco-
logic Control of Ventricular Rate,” 2005) provided clinical
recommendations for pharmacologic rate control of AF and
atrial ﬂutter, but they do not specify a target heart rate.24
Rhythm-Control Strategy
The new ACCF/AHA/HRS guidelines found no beneﬁt
in a routine rhythm-control strategy for patients with AF
with systolic heart failure compared with a rate-control
strategy. This recommendation was determined from the
Atrial Fibrillation and Congestive Heart Failure Trial, which
found that a routine rhythm-control strategy did not reduce
the death rate from cardiovascular causes compared with
a rate-control strategy in patients with AF and congestive
heart failure.25 In that study, rhythm-control therapy
included electrical cardioversion in patients who did not
achieve sinus rhythm after antiarrhythmic drug therapy,
repeat cardioversion if needed, and possible referral for
nonpharmacologic therapy. Amiodarone was the antiar-
rhythmic drug of choice, and either sotalol or dofetilide was
used if necessary. Rate-control therapy included adjusted
doses of b blockers with digitalis to achieve the targeted
heart rate (<80 beats/min at rest or <110 beats/min during
a 6-minute walk).The primary end point (death from
cardiovascular causes) was not signiﬁcantly different
between the rhythm-control (27%) and rate-control (25%)
strategies (mean follow-up 37 months; hazard ratio [HR] for
rhythm-control group 1.06, 95% conﬁdence interval [CI]
0.86 to 1.30, p ¼ 0.59, log-rank test).14,25
The CCS has recommended a rhythm-control strategy for
patients with AF who remain symptomatic with rate-control
therapy or in whom rate-control therapy is unlikely to
control their symptoms.9 Similarly, the ESC has recom-
mended that rhythm-control therapy can be added to rate-
control therapy if the patient is symptomatic despite
adequate rate control, or if a rhythm-control strategy is
selected because of factors such as the degree of symptoms,
younger age, or greater activity levels.
Additionally, the ACCF/AHA/HRS has recommended
that permanent AF be managed by rate control, unless it isdeemed possible to restore sinus rhythm. Paroxysmal AF
can be managed by rate-control or rhythm-control therapy.
The latter is especially attractive in highly symptomatic
patients with little or no associated underlying heart
disease.26
Although the ACCP did not provide speciﬁc recommen-
dations for rhythm-control therapy in patients with AF, they
noted that the results of the Atrial Fibrillation Follow-up
Investigation of Rhythm Management (AFFIRM) trial indi-
cated that patients with AF at high risk of stroke generally
beneﬁt from anticoagulation even after sinus rhythm has been
restored.15,27 The ACCP has recommended that long-term
antithrombotic therapy be determined by the patient’s
underlying risk of stroke and not the underlying rhythm.
Stroke Prevention: New Recommendations for
Combining Anticoagulant With Antiplatelet Therapy
In patients with AF in whom oral anticoagulation therapy
with warfarin is unsuitable, the ACCF/AHA/HRS has rec-
ommended that the addition of clopidogrel to aspirin to
reduce the risk of major vascular events, including stroke,
could be considered. The basis for this recommendation was
the results from the Atrial Fibrillation Clopidogrel Trial with
Irbesartan for Prevention of Vascular Events (ACTIVE W)
and Effect of Clopidogrel Added to Aspirin in Patients with
Atrial Fibrillation (ACTIVE A) trials.28,29 The results of the
ACTIVE W trial indicate that oral antithrombotic therapy
with aspirin (75 to 100 mg/day) plus clopidogrel (75 mg/
day) was inferior to warfarin (target international normal-
ized ratio 2.0 to 3.0) for the prevention of vascular events in
patients eligible for either therapeutic approach (primary
events, relative risk [RR] 1.44, 95% CI 1.18 to 1.76, p ¼
0.0003). The results of the ACTIVE A trial have indicated
that aspirin plus clopidogrel reduced the risk of major
vascular events (clopidogrel, RR 0.89, 95% CI 0.81 to 0.98,
p ¼ 0.01), especially stroke (RR 0.72, 95% CI 0.62 to 0.83,
p <0.001), and increased the risk of major hemorrhage (RR
1.57, 95% CI 1.29 to 1.92, p <0.001) compared with aspirin
alone in patients with AF considered unsuitable for oral
anticoagulation therapy with warfarin.
In November 2012, the ECS published a focused update
to the 2010 ECS guidelines.30 Given the availability of new
oral anticoagulation therapy, the ESC has now recom-
mended that aspirin plus clopidogrel therapy for stroke
prevention in AF should be limited to patients who refuse
oral anticoagulation therapy.
The ACCP has recommended combination therapy with
aspirin plus clopidogrel for patients with AF who are
unsuitable for, or who choose not to take, oral anti-
coagulation therapy (for reasons other than concerns about
major bleeding).
In contrast, the CCS has not recommended aspirin plus
clopidogrel therapy for patients with AF for whom warfarin
is considered unsuitable. In such cases, the CCS has rec-
ommended the use of dabigatran, because it might reduce
the risk of stroke at a lower risk of bleeding compared with
warfarin.6,31,32 In fact, the CCS has recommended that
dabigatran should be preferred to warfarin in most patients
who need antithrombotic therapy for AF. The CCS has also
noted that the bleeding risk is very similar or even increased
Table 4
Key clinical trials with dronedarone
Study Full Study Name Key Findings
ADONIS34 American-Australian-African Trial With Dronedarone
in Atrial Fibrillation or Flutter Patients for the
Maintenance of Sinus Rhythm
Dronedarone was signiﬁcantly more effective than placebo in
maintaining sinus rhythm; dronedarone prolonged time to
recurrence of AF (HR 0.75, p <0.001)
ANDROMEDA35 Antiarrhythmic Trial with Dronedarone in Moderate
to Severe CHF Evaluating Morbidity Decrease
Dronedarone increased early mortality in patients with recently
decompensated heart failure and depressed LV function (median
follow-up time 2 mos, HR 2.13, p ¼ 0.03)
ATHENA36,37 A placebo-controlled, double-blind, parallel-arm Trial
to assess the efﬁcacy of dronedarone 400 mg twice
daily for the prevention of cardiovascular Hospitalization
or death from any cause in patiENts with Atrial
ﬁbrillation/atrial ﬂutter
Dronedarone reduced death and cardiovascular hospitalizations in
patients with paroxysmal or persistent AF, or atrial ﬂutter and risk
factors for thromboembolism (HR 0.76, p <0.001); fewer strokes
occurred in the dronedarone group, although this effect was not
prespeciﬁed and requires conﬁrmation by other trials (HR 0.66,
p ¼ 0.027)*
DAFNE38 Dronedarone Atrial FibrillatioN study after Electrical
cardioversion
Administration of dronedarone in patients with persistent AF
converted only 5.8% to sinus rhythm (3.1% converted with
placebo) and did not improve acute success of electrical
cardioversion; increased time to AF relapse with dronedarone
800 mg (RR 55%, p ¼ 0.001)
DIONYSOS39 Efﬁcacy and Safety of Dronedarone Versus Amiodarone
for the Maintenance of Sinus Rhythm in Patients With
Persistent Atrial Fibrillation
Dronedarone was less effective than amiodarone in decreasing AF
recurrence in patients with persistent AF (recurrence of AF, HR
1.59, p <0.0001), but it was better tolerated
EURIDIS34 European Trial In Atrial Fibrillation or Flutter Patients
Receiving Dronedarone for the Maintenance of Sinus
Rhythm
Dronedarone was signiﬁcantly more effective than placebo in
maintaining sinus rhythm; dronedarone prolonged time to
recurrence of AF (HR 0.78, p ¼ 0.01)
PALLAS40,41 Permanent Atrial ﬁbriLLAtion outcome Study using
dronedarone on top of standard therapy
Trial stopped early because of twofold increase of cardiovascular
adverse events in patients receiving dronedarone compared with
patients receiving placebo; ﬁnal results show dronedarone
signiﬁcantly increased stroke (HR 2.32, p ¼ 0.02), heart failure
(HR 2.16, p <0.001), death (HR 1.94, p ¼ 0.049), and unplanned
cardiovascular hospitalization (HR 1.97, p <0.001) compared
with placebo
CHF ¼ congestive heart failure; LV ¼ left ventricular.
* The ATHENA trial excluded patients with decompensated heart failure within the previous 4 weeks or with class IV heart failure.
1664 The American Journal of Cardiology (www.ajconline.org)with aspirin plus clopidogrel compared with anticoagulation
with warfarin.6,32
For patients with a history of AF who have recently
undergone percutaneous coronary intervention, the CCS has
recommended a period of triple therapy (combined use of
warfarin with dual antiplatelet therapy) for optimal prophy-
laxis in patients at a high risk of stroke.6 The guidelines
deferred speciﬁcation of the duration of the triple therapy,
indicating that the decision should be determined by balancing
the risk of a stent-related event and the risk of bleeding.
The ESC concluded that triple therapy might have an
acceptable risk/beneﬁt ratio, provided the duration of treatment
is short and the bleeding risk is low. Triple therapy is recom-
mended for patients with AF after coronary artery stenting in
situations with moderate to high thromboembolic risk. The
duration of treatment should be similar to dual therapy, except
that the times are all shortened because of the bleeding risks
associated with long-term triple therapy. For bare metal stents,
1 month of triple therapy is appropriate; however, drug-eluting
stents require 3 months (for the “-olimus” group: sirolimus,
everolimus, tacrolimus) or 6 months (paclitaxel) of triple
therapy. Triple therapy has also been recommended in the
initial period (3 to 6 months) after an acute coronary syndrome
with or without percutaneous coronary intervention.13
Similarly, the ACCP has recommended triple therapy
(vitamin K antagonist, aspirin, and clopidogrel) for patientswith AF at a high risk of stroke (CHADS2 [congestive heart
failure, hypertension, age 75 years or older, diabetes,
previous stroke/transient ischemic attack/thromboembolism]
score 2) during the ﬁrst month after placement of a bare
metal stent or the ﬁrst 3 to 6 months after placement of
a drug-eluting stent (i.e., when the risk of stent thrombosis is
greatest.).15 The guidelines noted that patients with AF who
have received a drug-eluting stent and who are at increased
risk of late stent thrombosis (e.g., acute coronary syndrome
at presentation, diabetes, long lesions, narrow diameter of
target vessel)33 might choose to continue triple therapy for
a full 12 months after stent placement if they place a low
value on avoiding bleeding.
The ACCF/AHA/HRS did not make speciﬁc recom-
mendations regarding triple therapy for patients with AF and
stents. The guidelines only noted that this strategy has been
associated with an increase in bleeding complications that
can range from mild or moderate to severe or life-threat-
ening and that no prospective randomized controlled trials
have been reported addressing the bleeding risk of combi-
nation therapy.32,34
New Recommendations for Dronedarone
The ACCF/AHA/HRS, ESC, and CCS have now
included the use of dronedarone in the management of AF.
Table 5
HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile international normalized ratio, elderly, and
drugs/alcohol) bleeding risk score
Letter Clinical Characteristic Assigned Points
H Hypertension* 1
A Abnormal renal and liver function (1 point each)† 1 or 2
S Stroke 1
B Bleedingz 1
L Labile INRsx 1
E Elderly (age >65 yrs) 1
D Drugs or alcohol (1 point each)k 1 or 2
INR ¼ international normalized ratio.
* Hypertension is deﬁned as systolic blood pressure of >160 mm Hg.
† Abnormal kidney function deﬁned as the presence of chronic dialysis,
renal transplantation, or serum creatinine of 200 mmol/L; abnormal liver
function deﬁned as chronic hepatic disease (e.g., cirrhosis) or biochemical
evidence of signiﬁcant hepatic derangement (e.g., bilirubin 2 times the
upper limit of normal, in association with aspartate aminotransferase/alanine
aminotransferase/alkaline phosphatase 3 times the upper limit of normal).
z Bleeding refers to bleeding history and/or predisposition to bleeding
(e.g., bleeding diathesis, anemia).
x Labile INRs refers to unstable/high INRs or poor time in therapeutic
range (e.g., 60%).
k Drug/alcohol use refers to concomitant use of drugs, such as antiplatelet
agents, nonsteroidal anti-inﬂammatory drugs, or alcohol abuse.
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one. The new ACCF/AHA/HRS guidelines have indicated
that dronedarone might decrease the need for hospitaliza-
tions for cardiovascular events in patients with paroxysmal
AF or after conversion of persistent AF. However, drone-
darone is not recommended for patients with class IV heart
failure or patients who have had an episode of decom-
pensated heart failure in the previous 4 weeks, especially in
the presence of depressed left ventricular function (left
ventricular ejection fraction 35%).14 The recommenda-
tions regarding dronedarone use were based on the results
from several recent clinical trials35e42 (Table 4).
The results of the Permanent Atrial ﬁbriLLAtion
Outcome Study Using Dronedarone on Top of Standard
Therapy (PALLAS) trial, published after the guidelines
were updated, have demonstrated that dronedarone is
detrimental in patients with permanent AF42 (Table 4).
Thus, dronedarone should be reserved for selected low-risk
patients with persistent or paroxysmal AF, possibly those in
whom other antiarrhythmic drugs have failed, when the
intention is to maintain sinus rhythm.43,44
The 2012 ESC focused update has strengthened its
guideline that dronedarone should not be used in class III to
IV or unstable heart failure. Although dronedarone is useful
to decrease the heart rate at rest and with exercise during AF
relapses, it is contraindicated in patients with permanent
AF.13,30 The ESC has also advised that dronedarone
management should be supervised by a specialist (i.e.,
hospital or ofﬁce-based staff familiar with the use of anti-
arrhythmic drugs).
In March 2012, the CCS published a focused update to
the 2010 CCS guidelines. Based largely on the results of the
PALLAS trial, the update added the recommendations that
dronedarone (1) should not be used in patients with
permanent AF nor for the sole purpose of rate control, (2)should not be used in patients with a history of heart failure
or a left ventricular ejection fraction 0.40, and (3) should
be used with caution in patients taking digoxin.
Updated Recommendations for Catheter-Based
Ablation Therapy for Maintenance of Sinus Rhythm in
AF
The ACCF/AHA/HRS has expanded the recommenda-
tions on the use of catheter-based ablation in the manage-
ment of AF.14 Catheter ablation is recommended for patients
(1) with symptomatic, paroxysmal AF in whom 1antiar-
rhythmic drug has failed, (2) with symptomatic, persistent
AF, and (3) with symptomatic, paroxysmal AF with
signiﬁcant left atrial dilation or signiﬁcant left ventricular
dysfunction.14 The ACCF/AHA/HRS also added a new
section on the future directions of catheter-based ablation in
the management of AF.
The ACCF/AHA/HRS, ESC, and CCS are in general
agreement that catheter ablation should be reserved for
symptomatic patients with paroxysmal AF, although
differences were present in the determination of the criteria
for select patient populations. Similar to the ACCF/AHA/
HRS, the CCS has recommended catheter ablation for
patients who remain symptomatic during antiarrhythmic
drug therapy and for whom rhythm control remains desir-
able. The CCS has also suggested catheter ablation as the
ﬁrst-line therapy for highly selected patients with symp-
tomatic, paroxysmal AF (i.e., patients with a strong intol-
erance or aversion to antiarrhythmic drugs).
TheESCguidelines have elevated catheter ablation toﬁrst-
line treatment of some patients and did not specify a trial of
antiarrhythmic medication as a prerequisite. As an alternative
to antiarrhythmic drugs, catheter ablation can be offered to
patients with paroxysmal AF and no or minimal heart disease
who continue to be highly symptomatic despite rate-control
medications. The 2012 focused update upgraded these
recommendations but restricted them to experienced centers/
investigators, appropriate patient selection, careful evaluation
of treatment alternatives, and patient preference. The guide-
lines characterized catheter ablation for persistent and long-
standing persistent AF as being “less well established.”
The ACCP guidelines do not provide speciﬁc recom-
mendations for the use of catheter-ablation therapy in the
management of AF. The guidelines observed that in
randomized controlled trials, although catheter ablation was
found to signiﬁcantly reduce AF recurrence at w1 year of
follow-up, the AF recurrence rate ranged from 11% to 44%
atw1 year. Because of the results of the AFFIRM trial, the
lack of longer term follow-up data from catheter ablation
randomized controlled trials regarding AF recurrence rates,
and the poor reporting of stroke outcomes, the ACCP has
recommended that for patients with AF receiving catheter
ablation (or other rhythm-control strategies), decisions about
long-term antithrombotic therapy should be determined by
the underlying risk of stroke and not the underlying rhythm.
New Recommendations for Dabigatran
With approval by the Food and Drug Administration for
dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharma
GmbH, Biberach an der Riss, Germany) to reduce the risk of
Table 6
Recommendations for risk assessment guiding choice of antithrombotic therapy
CHADS2
score
Recommended Therapy for Patients With AF
ACCF/AHA/HRS ESC* ACCP CCS
0 Aspirin, 81e325 mg/day No antithrombotic therapy Aspirin, 75e325 mg/day or no
antithrombotic therapy; no
antithrombotic therapy is
preferred over aspirin
Aspirin, 75e325 mg/day
1 Aspirin, 81e325 mg/day,
or warfarin (INR 2.0e3.0,
target 2.5) or dabigatran
No antithrombotic therapy (if
age <65 yrs and lone AF)
or OAC. Dabigatran, rivaroxaban,
apixaban,† or warfarin (INR 2.0e3.0);
determined by assessment of risk of
bleeding complications and patient
preference
OAC (INR 2.0e3.0). Dabigatran
is suggested. For patients unsuitable
for, or who choose not to take, an
OAC, combination therapy with
clopidogrel and aspirin
(75e325 mg/day) preferred over
aspirin alone
OAC. Dabigatran, rivaroxaban,
or apixabanz according to
individual risk/beneﬁt
considerations; aspirin is a
reasonable alternative for
some patients
2 Warfarin (INR 2.0e3.0,
target 2.5) or dabigatran
OAC. Dabigatran, rivaroxaban, or
apixaban† in preference to warfarin
(INR 2.0e3.0), based on the patient’s
net clinical beneﬁt
OAC (INR 2.0e3.0). Dabigatran in
preference to warfarin, if severe
renal impairment absent. If OAC
is unsuitable or not patient choice,
combination therapy with clopidogrel
and aspirin (75e325 mg/day)
OAC. Dabigatran, rivaroxaban,
and apixabanz are preferred
over warfarin for most
patients
INR ¼ international normalized ratio; OAC ¼ oral anticoagulation therapy.
* For ESC, score refers to CHA2DS2-VASc score.
† In the 2012 focused update of the ESC guidelines, apixaban was included for stroke prevention in AF pending regulatory approval (approval in Europe
obtained in November 2012, after publication of 2012 ESC update).
z The 2012 CCS focused update recommended apixaban once approved by Health Canada (approved December 2012).
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AF, the ACCF/AHA/HRS now recommends that dabigatran
is a useful alternative to warfarin to reduce the risk of stroke
and systemic embolism in patients with nonvalvular AF.4
Dabigatran etexilate is a prodrug that is rapidly converted
to an active direct thrombin (factor IIa) inhibitor. Unlike
warfarin, which undergoes predominantly hepatic elimina-
tion, dabigatran is excreted renally. For patients with
a creatinine clearance of >30 ml/min, the approved dose is
150 mg twice daily. For patients with a creatinine clearance
of 15 to 30 ml/min, the approved dose is 75 mg twice daily.
These recommendations regarding dabigatran were largely
based on the results from the Randomized Evaluation of
Long-term anticoagulant therapy (RE-LY) study—a multi-
national, parallel-group, randomized controlled trial
comparing 2 blinded doses of dabigatran (110 and 150 mg
twice daily) with open label warfarin (dosed to a target
international normalized ratio of 2 to 3) in patients with AF
and 1 additional stroke risk factor.45 The results from that
study indicated that dabigatran 150 mg was superior to
warfarin for the prevention of ischemic stroke and systemic
embolism (dabigatran 150 mg, RR 0.65, 95%CI 0.52 to 0.81,
p <0.001 for superiority) with a similar rate of major
bleeding (3.57% with warfarin; 3.32% with 150 mg dabi-
gatran). The patients randomized to dabigatran 110 mg
experienced fewer major bleeding episodes than the warfarin
group, and this dose was noninferior for stroke reduction
(dabigatran 110 mg, RR 0.91, 95% CI 0.74 to 1.11, p<0.001
for noninferiority). The rates of intracranial hemorrhage were
lower with dabigatran than with warfarin (p <0.001 for both
doses of dabigatran compared with warfarin).
Dabigatran is also licensed for use in Canada. The CCS
has recommended dabigatran in preference to warfarin, withthe possible exceptions of patients with a propensity to
dyspepsia or gastrointestinal bleeding and those at
substantial risk of coronary events. The guidelines recom-
mended 150 mg twice daily for most patients and 110 mg
twice daily for patients 80 years old or patients with a low
body weight, decreased renal function, or an increased risk
of major bleeding.6 (The 110-mg dosage form of dabigatran
is not available in the United States.)
For cases in which oral anticoagulation therapy is rec-
ommended, the ACCP guidelines suggest dabigatran
150 mg twice daily rather than vitamin K antagonist
therapy, with the exception of patients with AF and mitral
stenosis, stents, or CHADS2 1 who experience an acute
coronary syndrome. The guidelines noted that clinicians
should be aware that no antidote is available for dabigatran.
The ESC guidelines were published before the approval
of dabigatran in Europe (approved August 2011). The 2012
focused update to the ESC guidelines recommended dabi-
gatran in preference to warfarin for stroke prevention in
AF.30 The guidelines used the HAS-BLED (Hypertension,
Abnormal renal/liver function, Stroke, Bleeding history or
predisposition, Labile international normalized ratio,
Elderly, and Drugs/alcohol; Table 5) bleeding risk scoring
system and stroke risk to stratify the recommendations for
thromboprophylaxis.13 If a patient has a low risk of bleeding
(e.g., HAS-BLED score 0 to 2), dabigatran 150 mg twice
daily is recommended; if a patient has a greater risk of
bleeding (e.g., HAS-BLED score 3), dabigatran 110 mg
twice daily is recommended.
New Recommendations for Rivaroxaban and Apixaban
Since the publication of the guidelines, rivaroxaban was
approved for use in the United States, Canada, and
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focused updates to their guidelines, recommending rivarox-
aban in preference to warfarin for stroke prevention in
patients with AF. Although rivaroxaban was not shown to be
superior to warfarin, the double-blind Rivaroxaban Once
Daily Oral Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism for Prevention of Stroke and Embo-
lism Trial in Atrial Fibrillation (ROCKET AF) trial demon-
strated that rivaroxaban was noninferior to warfarin for the
prevention of stroke or systemic embolism (rivaroxaban, HR
0.79, 95% CI 0.66 to 0.96, p <0.001 for noninferiority).48
Signiﬁcantly, the rivaroxaban group had similar rates of
major bleeding (HR 1.03, 95% CI 0.96 to 1.11, p¼ 0.44) and
signiﬁcant reductions in intracranial hemorrhage (0.5% vs
0.7%, p¼ 0.02) and fatal bleeding (0.2% vs 0.5%, p¼ 0.003)
compared with the warfarin group. The use of rivaroxaban
was not yet covered by the ACCF/AHA/HRS or the ACCP.
The ESC and CCS focused updates noted that apixaban
is also recommended in preference to warfarin, pending
regulatory approval (approved in Europe in November 2012
and approved in Canada in December 2012).30,47 This
recommendation was based on the results from the Apix-
aban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) and the Apix-
aban Versus Acetylsalicylic Acid to Prevent Strokes in
Atrial Fibrillation Patients Who Have Failed or Are
Unsuitable for Vitamin K Antagonist Treatment (AVER-
ROES) double-blind trials.49,50 The ARISTOTLE trial
demonstrated that apixaban was superior to warfarin in
preventing stroke or systemic embolism (apixaban, HR
0.79, 95% CI 0.66 to 0.95, p <0.001 for noninferiority, and
p ¼ 0.01 for superiority), caused less bleeding (HR 0.69,
95% CI 0.60 to 0.80, p <0.001), and resulted in lower
mortality (HR 0.89, 95% CI 0.80 to 0.99, p ¼ 0.047) in
patients with AF.50 The AVERROES trial showed that in
patients with AF for whom warfarin therapy was unsuitable,
apixaban reduced the risk of stroke or systemic embolism
(apixaban, HR 0.45, 95% CI 0.32 to 0.62, p <0.001)
without signiﬁcantly increasing the risk of major bleeding
(apixaban, HR 1.13, 95% CI 0.74 to 1.75, p ¼ 0.57) or
intracranial hemorrhage (apixaban, HR 0.85, 95% CI 0.38 to
1.90, p ¼ 0.69).49 Apixaban was approved for use in the
United States in December 2012; however, its use is not yet
covered in the ACCF/AHA/HRS or ACCP guidelines.
Additional Updates to ESC, ACCP, and CCS Guidelines
The ACCF/AHA/HRS, CCS, and ACCP guidelines have
recommended the CHADS2 index for primary risk assess-
ment and selection of antithrombotic therapy (Table 6). The
CHADS2 risk factors include congestive heart failure,
hypertension, age 75 years, diabetes, and previous stroke/
transient ischemic attack/thromboembolism. Each risk factor
is assigned 1 point, except for stroke/transient ischemic
attack/thromboembolism, which is assigned 2 points. The
ACCF/AHA/HRS noted that the CHADS2 index is simple
and easy to use, with broad applicability.6 However, the
ACCP noted that for patients with a CHADS2 score of 1,
the presence of multiple non-CHADS2 risk factors for stroke
(e.g., age, sex) might favor oral anticoagulation therapy
rather than no therapy or aspirin.The ESC has now recommended the CHA2DS2-VASc
for assessment of stroke risk in patients with AF. This risk
scheme expands the CHADS2 index with the following risk
factors for stroke: vascular disease, age (65 to 74 years), and
sex category (female sex). Additionally, the CHADS2 factor
of age 75 years carries more weight (2 points) in the
CHA2DS2-VASc.
The ESC and CCS guidelines have also recommended
the use of the HAS-BLED scoring system (Table 5) to
evaluate the risk of bleeding. A HAS-BLED score of 3
indicates a high risk of bleeding with thromboprophylaxis.
The ESC also created the new category “longstanding
persistent AF” to describe AF persisting 1 year yet the
physician has determined that the pursuit of a rhythm-
control strategy is reasonable. This category is between
persistent and permanent AF and was added to better
recognize these patients as candidates for nonpharmacologic
treatment strategies.13,32
The 2012 ESC focused update also included the use of
vernakalant (approved in Europe September 2010) for the
conversion of AF to sinus rhythm and interventional
percutaneous left atrial appendage closure for patients with
thromboembolic risk who cannot be managed in the long
term with oral anticoagulation therapy.
Additionally, in the CCS focused update, accurate
assessments of renal function and the recognition of co-
morbid chronic kidney disease has been recommended for
patients with AF receiving oral anticoagulation therapy.
These recommendations stipulate that patients with AF
receiving oral anticoagulation therapy (1) should have their
renal function assessed at least annually by measuring the
serum creatinine and calculating their estimated glomerular
ﬁltration rate, (2) should be regularly considered for alter-
ation of oral anticoagulant and/or dose changes according to
the estimated glomerular ﬁltration rate, and (3) should
receive antithrombotic therapy that relates to the estimated
glomerular ﬁltration rate. The last should be done as
follows: for patients with an estimated glomerular ﬁltration
rate >30 ml/min, the antithrombotic therapy should be
similar to that for patients with normal renal function (i.e.,
according to their CHADS2 score); and for patients with an
estimated glomerular ﬁltration rate of 15e30 ml/min and
patients not receiving dialysis, the antithrombotic therapy
should be determined according to their CHADS2 score,
except that the preferred agent for these patients is warfarin.
Conclusions
Overall, the ACCF/AHA/HRS, ESC, CCS, and ACCP
guidelines are in general accord. However, where the guide-
lines differ, in addition to the obvious options and limitations
(e.g., drug approval, available dosages), clinicians need to
assess the individual patient’s riskebeneﬁt ratio. Patient
preferences and circumstances should also be considered.
Moreover, adequate thromboprophylaxis is vital to reduceAF
complications. Thromboprophylaxis for stroke is greatly
underused in patients with AF. In fact, a systematic review
found that most studies of patients with AF with a previous
stroke or transient ischemic attack reported treatment of
<60% of eligible patients.19 The newer guidelines and
comprehensive risk stratiﬁcation re-emphasize the available
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of antithrombotic therapy.
In general, the current ACCP guidelines have recom-
mended antithrombotic treatment less often and less strongly
than previously (e.g., the recommendations tend to be weaker
than in the previous ACCP guidelines). This trend is likely
a result of the increased methodologic rigor of the current
ACCP guidelines compared with previous ACCP guidelines.
It is also consistent with the recommendations of MacLean
et al,51 who, in accordance with their ﬁndings that patient
values and preferences regarding thromboprophylaxis treat-
ment are highly variable, suggested that guideline panels
should be circumspect in making strong recommendations
(these ﬁndings are included in the current ACCP guidelines).
In contrast, the ESC recommendations might result in more
patients with AF receiving anticoagulation therapy, because
of the use of the CHA2DS2-VASc score. The ESC has also
recommended that management of certain therapies (i.e.,
dronedarone, catheter ablation) be supervised and/or per-
formed by an experienced specialist. The ESC, ACCP, and
CCS have made speciﬁc recommendations regarding triple
therapy (aspirin, clopidogrel, and antithrombotic drugs) in
patients with AF and stents; however, the ACCF/AHA/HRS
guidelines only noted the increased bleeding risk with such
treatment and the lack of prospective trials. The ACCF/AHA/
HRS has recommended the use of dabigatran as an alternative
to warfarin. The ESC, ACCP, and CCS have recommended
dabigatran in preference to warfarin when oral anti-
coagulation therapy is indicated. Rivaroxaban was recently
approved for use in the United States, Europe, and Canada. In
the 2012 focused updates of their guidelines, the ESC and
CCS have recommended either dabigatran or rivaroxaban in
preference to warfarin.
Given that a large number of cases of stroke in patients with
AF could be preventable through the use of appropriate
thromboprophylaxis, these updated guidelines provide a valu-
able evaluation of recent scientiﬁc evidence for clinicians to
evaluate the appropriatemanagement options for their patients.Acknowledgment: Writing and editorial assistance was
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